LTR Pharma (ASX:LTP) has announced the successful completion of the pivotal clinical study for Spontan, the company’s novel intranasal formulation of vardenafil for the treatment of erectile dysfunction.
-
Latest News LTR Pharma says Spontan achieves faster absorption in completed pivotal study October 15, 2024
-
Latest News Respiri announces it has secured a major strategic investment October 15, 2024Respiri chairman Nicholas Smedley said, “The Board and I are pleased to welcome investors of this calibre onto our registry."
-
Latest News TGA approves new indication for Telix’s Illuccix to include patient selection for PSMA-targeted therapy October 10, 2024Telix has announced that the TGA has approved the use of Illuccix to select patients for PSMA-targeted radionuclide therapy.
-
AusBiotech Australia's premier life science investment event AusBioInvest 2024 October 10, 2024Australia's premier life science investment event, AusBioInvest 2024, kicks off on Tuesday, 29 October, in Melbourne.
-
Latest News Amplia Therapeutics CEO shares Prime Minister's Prize for Innovation October 10, 2024The CEO and managing director of Australian company Amplia Therapeutics (ASX:ATX), Dr Chris Burns, and Professor Andrew Wilks have shared the Prime Minister’s Prize for Innovation for their role in the discovery of JAK enzymes and their co-invention of the JAK inhibitor momelotinib.
-
Latest News Noxopharm contracts specialist manufacturer for SOF-SKN clinical trial October 10, 2024Noxopharm (ASX:NOX) has contracted a specialist supplier to manufacture SOF-SKN for the upcoming HERACLES clinical trial.
-
Latest News Firebrick Pharma announces the completion of share purchase plan October 10, 2024Firebrick Pharma (ASX:FRE) has announced the close of its Share Purchase Plan that was announced to the market on 12 September 2024.
-
AusBiotech Federal Minister for Health and Aged Care to speak at Australia’s biggest week in biotech October 8, 2024AusBiotech has announced Health Minister Mark Butler will join industry members, international delegates, and investors during Australia’s most significant week in biotechnology.
-
Latest News Chimeric says cancer patient achieves complete response in CHM CORE-NK trial October 8, 2024Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that a patient with Acute Myelogenous Leukemia has recorded a complete response in its Phase 1b CHM CORE-NK and Vactosertib combination.
-
Latest News Island Pharmaceuticals secures new funding to support key inflection points and pipeline build October 8, 2024Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has announced it has received commitments for a two-tranche placement to existing and new investors to raise approximately $3.5 million at $0.07 per share.
-
Latest News Cyclopharm signs agreement makes major progress with US veterans and defence administrations October 8, 2024Cyclopharm (ASX:CYC) has announced it has entered into an interim agreement to supply the Veterans Health Administration, the most extensive integrated government healthcare system in the US, with the pharmaceutical and consumable components of Technegas.
-
Latest News New drug could be answer to an overlooked yet devastating type of dementia October 8, 2024Monash University researchers are assessing a new drug that researchers believe could have an impact on a form of dementia.
-
Latest News New Alliance to drive increased procurement of homegrown medtech October 3, 2024The Australian Medtech Manufacturing Alliance has been established with the goal of growing opportunities for medtech manufacturers to sell to health services.
-
Latest News Australian company Vaxxas receives significant investment from Endpoints Capital October 3, 2024Life sciences financier Endpoints Capital has advanced pioneering Australian firm Vaxxas $9.7 million for its Research and Development Tax Incentive.
-
Latest News Nyrada’s says lead drug candidate demonstrates significant cardioprotection October 3, 2024Nyrada (ASX:NYR) has announced positive results from a preclinical rat study evaluating the efficacy of its lead drug candidate, NYR-BI03, in coronary heart disease.
-
Latest News Cartherics raises over $15 million in private financing round October 3, 2024CEO Professor Alan Trounson AO said, “The successful capital raising, in times of scant investment support in biotechnology, is welcome and further supports confidence in the company for the delivery of effective therapies in ovarian cancer and other difficult diseases.”
-
Latest News Artrya submits application for Salix to the US FDA October 1, 2024Australian medical technology company Artrya (ASX:AYA) has submitted its application for regulatory approval for the Salix Coronary Anatomy product to the US FDA.
New Stories
-
Immuron reports continued sales growth for Travelan
October 15, 2024 - - Latest News -
Respiri announces it has secured a major strategic investment
October 15, 2024 - - Latest News -
AusBiotech releases 2023-2024 annual report
October 15, 2024 - - AusBiotech -
AusBiotech calling on experts to become mentors for Industry Growth Program
October 15, 2024 - - Latest News -
LTR Pharma says Spontan achieves faster absorption in completed pivotal study
October 15, 2024 - - Latest News -
Australia's premier life science investment event AusBioInvest 2024
October 10, 2024 - - AusBiotech -
Firebrick Pharma announces the completion of share purchase plan
October 10, 2024 - - Latest News